1Y Annualised Return
▲63.88%
3Y Annualised Return
▲80.13%
5Y Annualised Return
▲51.96%
Marksans Pharma SIP Return Calculator
Over the past
Total Investment of ₹65,00,000
Would have become ₹91,06,068 (+40.09%)
Daily SIP of ₹25,000 would have become ₹91,06,068 in 1 year with a gain of ₹26,06,068 (+40.09%)
Open
252.00
Prev. Close
259.95
Total Traded Value
35.16 Cr
Market Cap (in crs)
11,748.27
Face Value
1
Turnover (in lacs)
3,516.08
Marksans Pharma Key Financials
*All values are in ₹ Cr.
*All values are in ₹ Cr.
*All values are in ₹ Cr.
*All values are in ₹ Cr.
Marksans Pharma Quarterly Revenue
| Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|
708.46 Cr | 681.85 Cr | 641.92 Cr | 590.62 Cr | 560.01 Cr |
Marksans Pharma Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
2693.22 Cr | 2227.83 Cr | 1911.45 Cr | 1532.69 Cr | 1382.88 Cr | 1134.54 Cr |
Marksans Pharma Quarterly Net Profit/Loss
| Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|
90.73 Cr | 105.07 Cr | 97.76 Cr | 89.07 Cr | 77.64 Cr |
Marksans Pharma Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
382.62 Cr | 314.9 Cr | 265.32 Cr | 186.81 Cr | 238.54 Cr | 120.75 Cr |
Result Summary
-
Marksans Pharma Ltd reported a 18.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 16.0%.
-
Its expenses for the quarter were down by 15.9% QoQ and up 21.2% YoY.
-
The net profit decreased 26.1% QoQ and decreased 6.1% YoY.
-
The earnings per share (EPS) of Marksans Pharma Ltd stood at 1.7 during Q4FY25.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Marksans Pharma Technical Analysis
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 611576 Rs | 1485016 Rs |
Week Rs | 657871 Rs | 1801418 Rs |
Month Rs | 534827 Rs | 1440508 Rs |
Similar stocks
Similar Stocks
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
- | 12,355.18 | 422 | 721 | 523.90 | -3.88% | 6.62% | -12.89% | 10.15% | 96.91% | 0.29% | 41.69 | 42.57 | 3.63 | |
- | 9,679.10 | 4863 | 6175.5 | 5,839.50 | 4.86% | 14.73% | 2.96% | 16.86% | 39.73% | 4.45% | 37.27 | 42.57 | 18.05 | |
- | 14,157.69 | 4902 | 7600 | 6,172.50 | 0.01% | 3.67% | -1.08% | -5.61% | -7.15% | 1.90% | 37.31 | 42.57 | 16.47 | |
- | 9,640.23 | 519.5 | 995.9 | 962.60 | 7.80% | 47.26% | 20.93% | 80.25% | 133.91% | 0.10% | 101.04 | 42.57 | 3.57 | |
- | 12,437.05 | 819.05 | 1335.1 | 1,028.80 | 0.81% | -10.82% | -0.39% | 18.19% | 124.55% | 0.49% | 25.58 | 42.57 | 4.41 | |
- | 11,644.28 | 4211.55 | 5520 | 5,098.50 | 0.36% | 3.06% | 4.86% | 0.00% | 0.00% | 1.08% | 62.26 | 42.57 | 42.75 |
Marksans Pharma Company background
Marksans Pharma Ltd
Marksans Pharma Limited, a globally recognized pharmaceutical company, has established itself as a key player in the pharmaceutical industry with a strong focus on research, manufacturing, marketing, and sale of pharmaceutical formulations. Originally incorporated as Tasc Pharmaceuticals Limited in April 1982, the company underwent a significant transformation when it was renamed Marksans Pharma Limited following a Scheme of Amalgamation that took effect on October 10, 2005. This transition marked the beginning of Marksans Pharma's journey to becoming a trusted name in healthcare, with its innovative solutions and commitment to quality playing a central role in its growth.
The Early Years and Strategic Amalgamation
In 2005, Marksans Pharma underwent a pivotal change when it amalgamated with M/s Marksans Pharma Limited (formerly Glenmark Laboratories Limited). This merger, approved by a High Court order on August 19, 2005, allowed Marksans Pharma to consolidate its resources, expand its capabilities, and issue necessary shares to the shareholders of the amalgamating entity. This strategic move provided a robust platform for the company’s future endeavors, enabling it to diversify its product portfolio and strengthen its position in the pharmaceutical market.
Global Expansion through Acquisitions
Marksans Pharma’s growth story is deeply intertwined with its strategic acquisitions that have helped it establish a strong international footprint. In 2005, the company acquired a majority stake in Nova Pharmaceuticals Australasia Private Limited, marking its entry into the Australian market. This acquisition enabled Marksans Pharma to tap into a new customer base and leverage Nova’s local expertise.
Building on this momentum, Marksans Pharma expanded further into the European market in 2008 by acquiring two UK-based companies: Bell, Sons & Company (Druggists) Limited and Relonchem Limited. These acquisitions provided the company with access to established distribution networks in the UK and Europe, allowing it to deliver high-quality pharmaceutical products to a broader audience.
Entry into the US Market and ANDA Milestone
Marksans Pharma’s global expansion continued with its entry into the US market, a significant milestone in its history. In 2011, the company achieved its first Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (USFDA), marking its readiness to compete in one of the most stringent and lucrative pharmaceutical markets globally.
In 2015, Marksans Pharma further solidified its presence in the US by acquiring Time-Cap Laboratories Inc., a move that not only expanded its production capabilities but also enhanced its ability to meet the growing demand for generic pharmaceuticals in the region. This acquisition underscored the company’s strategic focus on gaining a foothold in key international markets.
Innovative Product Launches and Expansion of R&D
Marksans Pharma’s commitment to innovation is evident in its continuous investment in research and development (R&D). In the financial year 2017-18, the company launched its CNS-Cerebella division, which was dedicated to developing and marketing products targeting the central nervous system. This division underscored Marksans Pharma’s focus on addressing complex healthcare challenges and meeting the unmet needs of patients globally.
The launch of soft gelatin capsules, a niche product category, further demonstrated the company’s ability to innovate and introduce unique formulations. During the same period, Marksans Pharma launched two new products and received a Complete Response Letter (CRL) for four ANDAs, bringing it closer to expanding its product range in the US market.
To support its innovation-driven growth, Marksans Pharma commissioned a new R&D center in Navi Mumbai in 2019-20, complementing its existing facility in Verna, Goa. These state-of-the-art facilities have enabled the company to focus on developing complex generics and novel drug delivery systems, aligning with its vision of becoming a leader in the pharmaceutical industry.
Recent Milestones and Strategic Acquisitions
Marksans Pharma continues to build on its legacy of excellence and strategic growth. In April 2023, the company acquired the business of Tevapharm India Private Limited, a move that significantly enhanced its manufacturing capabilities. This acquisition involved taking over Tevapharm’s pharmaceutical formulations business in Verna, Goa, as a going concern on a slump sale basis. By integrating this facility into its operations, Marksans Pharma reinforced its position as a leading manufacturer of high-quality pharmaceutical products.
Marksans Pharma Share Price: A Reflection of Growth
The Marksans Pharma Share Price serves as a reliable indicator of the company’s robust financial performance and its consistent efforts to create value for stakeholders. Over the years, the share price has been influenced by the company’s strategic acquisitions, innovative product launches, and successful expansion into international markets. The company’s ability to adapt to changing market dynamics and its relentless focus on quality and compliance have bolstered investor confidence, making Marksans Pharma a compelling choice in the pharmaceutical sector.
Commitment to Quality and Compliance
Marksans Pharma’s reputation for excellence is built on its unwavering commitment to quality and compliance. The company’s facilities in Goa and Navi Mumbai adhere to stringent regulatory standards, ensuring that its products meet the highest levels of safety and efficacy. Its R&D centers are equipped with advanced technologies and staffed by a team of skilled professionals dedicated to developing innovative solutions for diverse therapeutic areas.
Future Outlook and Vision
Looking ahead, Marksans Pharma is poised to continue its growth trajectory by leveraging its strong R&D capabilities, expanding its global footprint, and introducing innovative products. The company’s focus on complex generics, coupled with its strategic acquisitions, positions it to capture new opportunities in the pharmaceutical market.
With a robust product pipeline, a growing international presence, and a steadfast commitment to quality, Marksans Pharma is well-equipped to address the evolving needs of patients and healthcare providers worldwide. As the company embarks on its next phase of growth, the Marksans Pharma Share Price is expected to reflect its ongoing success and its ability to deliver sustainable value to its stakeholders.
Quick overview
Marksans Pharma Limited has come a long way since its inception as Tasc Pharmaceuticals Limited in 1982. Through strategic amalgamations, global acquisitions, innovative product launches, and a strong focus on R&D, the company has transformed into a global pharmaceutical powerhouse. Its relentless pursuit of excellence, combined with its ability to adapt to changing market dynamics, ensures its relevance in an increasingly competitive industry. As it continues to expand its global footprint and enhance its capabilities, Marksans Pharma remains committed to delivering high-quality pharmaceutical solutions that improve the lives of patients around the world.
As of 13 Jun, 2025, MARKSANS share price is ₹259.2. The stock opened at ₹252 and had closed at ₹260 the previous day. During today’s trading session, MARKSANS share price moved between ₹250.10 and ₹260.00, with an average price for the day of ₹255.00. Over the last 52 weeks, the stock has recorded a low of ₹155.46 and a high of ₹358.70. In terms of performance, MARKSANS share price has declined by 17% over the past six months and has increased by 63.88% over the last year.
Marksans Pharma FAQs
What is Share Price of Marksans Pharma ?
Marksans Pharma share price is ₹259.1 in NSE and ₹258.85 in BSE as on 13/6/2025.
How has Marksans Pharma shares performed in the past ?
Marksans Pharma share price in the past 1-year return was 63.44. The Marksans Pharma share hit a 1-year low of Rs. 155.46 and a 1-year high of Rs. 358.7.
What is the market cap of Marksans Pharma ?
The market cap of Marksans Pharma is Rs. 11748.27 Cr. as of 13/6/2025.
What is the current P/E ratio of Marksans Pharma ?
The PE ratios of Marksans Pharma is 62.45 as of 13/6/2025.
What is the current PB ratio of Marksans Pharma ?
The PB ratios of Marksans Pharma is 8.48 as of 13/6/2025
What is the Mutual Fund shareholding in Marksans Pharma ?
The Mutual Fund Shareholding in Marksans Pharma was 3.37% at the end of 13/6/2025.
How to buy Marksans Pharma shares?
You can easily buy Marksans Pharma shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
Please be aware that Marksans Pharma stock prices are subject to continuous fluctuations due to various factors.